[ad_1]
Madrid– A team led by Spanish researchers has succeeded for the first time, in mice, to completely eliminate pancreatic cancer, an advance that opens the way to the development of effective treatments against this type of tumors, which presents a very high mortality rate.
The team, led by Dr. Mariano Barbacid, head of the AXA group at the National Center for Oncological Research (CNIO), made this discovery by combining the elimination of two molecular targets (called EGFR and c-RAF) linked to the responsible gene. from the initiation of more than 95% of this type of tumors (the oncogene KRAS).
Barbacid insisted yesterday, during a press appearance, to present the results, which constitutes "a first step", in which we must continue our research, in which the application of this type of therapies will not be available for humans for a period of at least five years and for which, therefore, it does not serve patients who currently suffer from this type of cancer.
Pancreatic cancer, one of the most aggressive cancers in the world, affects approximately 8,000 people in Spain each year and its 5-year survival rate is only 5%.
"The ductal adenocarcinoma of the pancreas" is one of the most resistant cancers to current treatments. Currently, its cure is limited to cases in which the tumor is very localized and can be removed surgically. it represents less than 10% of patients.
In the United States, it is already the third leading cause of death, behind lung cancer and colon cancer, and its mortality exceeds that of bad cancer in Spain.
To present the results of the investigation published yesterday in front of the media, besides Barbacid, Dr. Alfredo Carrato, head of the oncology department of Ramón y Cajal Hospital of Madrid and director of the. Ramón y Cajal Health Research Institute, and the doctor Marta Puyol, Research Director of the Spanish Association Against Cancer. -Efe
Source link
